TY  - JOUR
AU  - Aslam, Aqsa
AU  - Masood, Farha
AU  - Perveen, Kousar
AU  - Berger, Martin
AU  - Pervaiz, Asim
AU  - Zepp, Michael
AU  - Klika, Karel D
AU  - Yasin, Tariq
AU  - Hameed, Abdul
TI  - Preparation, characterization and evaluation of HPβCD-PTX/PHB nanoparticles for pH-responsive, cytotoxic and apoptotic properties.
JO  - International journal of biological macromolecules
VL  - 270
IS  - Part 2
SN  - 0141-8130
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - DKFZ-2024-01037
SP  - 132268
PY  - 2024
N1  - Volume 270, Part 2, June 2024, 132268
AB  - Paclitaxel (PTX) is a potent anticancer drug. However, PTX exhibits extremely poor solubility in aqueous solution along with severe side effects. Therefore, in this study, an inclusion complex was prepared between PTX and hydroxypropyl-β-cyclodextrin (HPβCD) by solvent evaporation to enhance the drug's solubility. The HPβCD-PTX inclusion complex was then encapsulated in poly-3-hydroxybutyrate (PHB) to fabricate drug-loaded nanoparticles (HPβCD-PTX/PHB NPs) by nanoprecipitation. The HPβCD-PTX/PHB NPs depicted a higher release of PTX at pH 5.5 thus demonstrating a pH-dependent release profile. The cytotoxic properties of HPβCD-PTX/PHB NPs were tested against MCF-7, MDA-MB-231 and SW-620 cell lines. The cytotoxic potential of HPβCD-PTX/PHB NPs was 2.59-fold improved in MCF-7 cells in comparison to free PTX. Additionally, the HPβCD-PTX/PHB NPs improved the antimitotic (1.68-fold) and apoptotic (8.45-fold) effects of PTX in MCF-7 cells in comparison to PTX alone. In summary, these pH-responsive nanoparticles could be prospective carriers for enhancing the cytotoxic properties of PTX for the treatment of breast cancer.
KW  - HPβCD-drug inclusion complex (Other)
KW  - Nano-system (Other)
KW  - PHB (Other)
KW  - Paclitaxel (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38734336
DO  - DOI:10.1016/j.ijbiomac.2024.132268
UR  - https://inrepo02.dkfz.de/record/290204
ER  -